These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 38162649)

  • 1. Leveraging a gene signature associated with disulfidptosis identified by machine learning to forecast clinical outcomes, immunological heterogeneities, and potential therapeutic targets within lower-grade glioma.
    Zhou Y; Cao Y; Liu W; Wang L; Kuang Y; Zhou Y; Chen Q; Cheng Z; Huang H; Zhang W; Jiang X; Wang B; Ren C
    Front Immunol; 2023; 14():1294459. PubMed ID: 38162649
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recurrence- and Malignant Progression-Associated Biomarkers in Low-Grade Gliomas and Their Roles in Immunotherapy.
    Teng C; Zhu Y; Li Y; Dai L; Pan Z; Wanggou S; Li X
    Front Immunol; 2022; 13():899710. PubMed ID: 35677036
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multiomics Analysis of Disulfidptosis Patterns and Integrated Machine Learning to Predict Immunotherapy Response in Lung Adenocarcinoma.
    Liu J; Li H; Zhang N; Dong Q; Liang Z
    Curr Med Chem; 2024; 31(25):4034-4055. PubMed ID: 38685772
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Machine learning- and WGCNA-mediated double analysis based on genes associated with disulfidptosis, cuproptosis and ferroptosis for the construction and validation of the prognostic model for breast cancer.
    Xu L; Wang S; Zhang D; Wu Y; Shan J; Zhu H; Wang C; Wang Q
    J Cancer Res Clin Oncol; 2023 Dec; 149(18):16511-16523. PubMed ID: 37712959
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of disulfidptosis-related genes and immune infiltration in lower-grade glioma.
    Li XM; Liu SP; Liu DM; Li Y; Cai XM; Su Y; Xie ZF
    Open Med (Wars); 2023; 18(1):20230825. PubMed ID: 37900961
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Signature Construction and Disulfidptosis-Related Molecular Cluster Identification for Better Prediction of Prognosis in Glioma.
    Zhuang Y; Chen J; Mai Z; Huang W; Zhong W
    J Mol Neurosci; 2024 Apr; 74(2):38. PubMed ID: 38573391
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Construction of disulfidptosis-based immune response prediction model with artificial intelligence and validation of the pivotal grouping oncogene c-MET in regulating T cell exhaustion.
    Li P; Wang S; Wan H; Huang Y; Yin K; Sun K; Jin H; Wang Z
    Front Immunol; 2024; 15():1258475. PubMed ID: 38352883
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bioinformatics-based analysis of the relationship between disulfidptosis and prognosis and treatment response in pancreatic cancer.
    Xiong Y; Kong X; Mei H; Wang J; Zhou S
    Sci Rep; 2023 Dec; 13(1):22218. PubMed ID: 38097783
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The disulfidptosis-related signature predicts prognosis and immune features in glioma patients.
    Wang X; Yang J; Yang F; Mu K
    Sci Rep; 2023 Oct; 13(1):17988. PubMed ID: 37864127
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Disulfidptosis characterizes the tumor microenvironment and predicts immunotherapy sensitivity and prognosis in bladder cancer.
    Pan G; Xie H; Xia Y
    Heliyon; 2024 Feb; 10(3):e25573. PubMed ID: 38356551
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Classification related to immunogenic cell death predicts prognosis, immune microenvironment characteristics, and response to immunotherapy in lower-grade gliomas.
    Kuang Y; Jiang B; Zhu H; Zhou Y; Huang H; Li C; Zhang W; Li X; Cao Y
    Front Immunol; 2023; 14():1102094. PubMed ID: 37153540
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Unraveling pathogenesis, biomarkers and potential therapeutic agents for endometriosis associated with disulfidptosis based on bioinformatics analysis, machine learning and experiment validation.
    Zhao X; Zhao Y; Zhang Y; Fan Q; Ke H; Chen X; Jin L; Tang H; Jiang Y; Ma J
    J Biol Eng; 2024 Jul; 18(1):42. PubMed ID: 39061076
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Leveraging a disulfidptosis-related signature to predict the prognosis and immunotherapy effectiveness of cutaneous melanoma based on machine learning.
    Zhao Y; Wei Y; Fan L; Nie Y; Li J; Zeng R; Li J; Zhan X; Lei L; Kang Z; Li J; Zhang W; Yang Z
    Mol Med; 2023 Oct; 29(1):145. PubMed ID: 37884883
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development and validation of a prognostic gene expression signature for lower-grade glioma following surgery and adjuvant radiotherapy.
    Qian DC; Marascio JA; Tobillo R; Lorenz JW; McCall NS; Neill SG; Hoang KB; Olson JJ; Eaton BR; Shu HG; Zhong J
    Radiother Oncol; 2022 Oct; 175():93-100. PubMed ID: 35998839
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunogenic cell death-related risk signature predicts prognosis and characterizes the tumour microenvironment in lower-grade glioma.
    Cai J; Hu Y; Ye Z; Ye L; Gao L; Wang Y; Sun Q; Tong S; Yang J; Chen Q
    Front Immunol; 2022; 13():1011757. PubMed ID: 36325335
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Machine learning identification and immune infiltration of disulfidptosis-related Alzheimer's disease molecular subtypes.
    Zhu Y; Kong L; Han T; Yan Q; Liu J
    Immun Inflamm Dis; 2023 Oct; 11(10):e1037. PubMed ID: 37904698
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Integrated machine learning-driven disulfidptosis profiling: CYFIP1 and EMILIN1 as therapeutic nodes in neuroblastoma.
    Mengzhen Z; Xinwei H; Zeheng T; Nan L; Yang Y; Huirong Y; Kaisi F; Xiaoting D; Liucheng Y; Kai W
    J Cancer Res Clin Oncol; 2024 Mar; 150(3):109. PubMed ID: 38427078
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of a novel cuproptosis-related gene signature and integrative analyses in patients with lower-grade gliomas.
    Bao JH; Lu WC; Duan H; Ye YQ; Li JB; Liao WT; Li YC; Sun YP
    Front Immunol; 2022; 13():933973. PubMed ID: 36045691
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Integrated analysis of inflammatory response subtype-related signature to predict clinical outcomes, immune status and drug targets in lower-grade glioma.
    Cao Y; Zhu H; Chen Q; Huang H; Xie D; Li X; Jiang X; Ren C; Peng J
    Front Pharmacol; 2022; 13():914667. PubMed ID: 36091778
    [No Abstract]   [Full Text] [Related]  

  • 20. Crosstalk of disulfidptosis-related subtypes, establishment of a prognostic signature and immune infiltration characteristics in bladder cancer based on a machine learning survival framework.
    Zhao S; Wang L; Ding W; Ye B; Cheng C; Shao J; Liu J; Zhou H
    Front Endocrinol (Lausanne); 2023; 14():1180404. PubMed ID: 37152941
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.